Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15723MR)

This product GTTS-WQ15723MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15723MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1565MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ92MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ8800MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ10936MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ4643MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ9314MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ2127MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ15992MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00521505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW